Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation discusses concerns about the effectiveness of finasteride for hair loss. The user is worried about being a non-responder to the treatment.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

Red flags to watch for when choosing a hair transplant clinic, such as high-pressure sales tactics, unclear surgeon assignments, and unrealistic promises. A user shared a positive experience with Skin Medics UK, highlighting transparency and personalized care.

Dutasteride in semen is considered a very small risk for partners, and fertility typically improves after stopping the medication. It is recommended to stop Dutasteride 3-6 months before trying to conceive to avoid potential impacts on fertility and fetal development.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

The conversation is about the potential risk of permanent hair loss from PRP (platelet rich plasma) treatments and whether PRF (platelet rich fibrin) carries the same risk. The user is seeking information on this topic.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

People discuss whether it's appropriate to suggest hair loss treatments like finasteride or minoxidil to others, especially young individuals. Opinions vary, with some advocating for sharing information and others cautioning against unsolicited advice due to potential side effects and personal sensitivities.

A person is worried about balding affecting their relationship and is using minoxidil, finasteride, and dutasteride. They are advised to be honest with their partner and focus on self-acceptance, as many people don't care about hair loss.

Concerns about finasteride's side effects on neurosteroids and brain health, with skepticism towards Kevin Mann's advice. Users discuss using finasteride, minoxidil, and RU58841 for hair loss, with mixed opinions on their safety and effectiveness.

The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.

The conversation is about a finding that finasteride does not significantly increase the risk of sexual dysfunction, with users sharing mixed personal experiences regarding side effects.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Dutasteride is considered safe for conception, with semen concentrations being too low to cause harm. Users discuss switching between dutasteride and finasteride, with some experiencing side effects like acne and heart issues, and advice is given to maintain a consistent treatment regimen.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

Most people using finasteride, minoxidil, or dutasteride for hair loss experience maintenance or regrowth, but they often don't discuss it publicly. Online forums may not accurately represent the typical success rates, as satisfied users rarely share their positive outcomes.

The conversation discusses whether individuals using hair loss treatments like Dutasteride (Dut) or Finasteride (Fin) should regularly check their hormone levels through bloodwork. Some argue it's important to monitor the effects of these medications on hormone levels, while others believe it's unnecessary if there are no side effects, citing cost and practicality concerns.